Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 2/3 1

Status

Withdrawn 1Suspended 1Recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 5Myeloid 3Classical hematology 1

Conditions

Myelodysplastic Syndromes 382Leukemia, Myeloid, Acute 356Precursor Cell Lymphoblastic Leukemia-Lymphoma 184Leukemia 149Leukemia, Myelogenous, Chronic, BCR-ABL Positive 147Leukemia, Myelomonocytic, Chronic 128Myeloproliferative Disorders 114Leukemia, Lymphocytic, Chronic, B-Cell 100Primary Myelofibrosis 99Multiple Myeloma 89Lymphoma, Non-Hodgkin 89Hodgkin Disease 76Blast Crisis 68Lymphoma 62Leukemia, Myeloid, Chronic-Phase 58Lymphoma, Large B-Cell, Diffuse 53Lymphoma, Mantle-Cell 52Lymphoma, Follicular 52Burkitt Lymphoma 52Hematologic Neoplasms 51Leukemia, Myeloid, Accelerated Phase 50Congenital Abnormalities 47Polycythemia Vera 45Lymphoma, B-Cell, Marginal Zone 44Thrombocythemia, Essential 43Lymphoma, Large-Cell, Immunoblastic 43Anemia, Refractory, with Excess of Blasts 42Myelodysplastic-Myeloproliferative Diseases 41Neoplasms, Plasma Cell 40Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 40

Interventions

Specimen Handling 2venetoclax 1regorafenib 1decitabine and cedazuridine drug combination 1Nivolumab 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × GATA2 Deficiency × Myeloid × Clear all
NCT06484062 2026-05-13

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 1 Recruiting
54 enrolled
MyeloidOther hematologic neoplasm

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06454409 2025-11-19

Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

City of Hope Medical Center

Phase 1 Suspended
20 enrolled
MyeloidOther hematologic neoplasm

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04361058 2023-12-05

Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide

SCRI Development Innovations, LLC

Phase 1 Withdrawn
MyeloidOther hematologic neoplasm

GATA2 Deficiency, Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡